Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).
Olanow
C Warren
CW
Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA.
Damier
Philippe
P
Goetz
Christopher G
CG
Mueller
Thomas
T
Nutt
John
J
Rascol
Olivier
O
Serbanescu
Alexandru
A
Deckers
Frieda
F
Russ
Hermann
H
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D008297:Male; D008499:Medical Records; D009930:Organic Chemicals; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D009930:Organic Chemicals; D007980:Levodopa; C443959:sarizotan